Canadian Cancer Trials Group Bulletins

General


Recent Publication

IND.193 - A Phase II Study of AT7519M, A CDK Inhibitor in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia

IND.194 - A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Relapsed Mantle Cell Lymphoma

IND.193 and IND.194, conducted concurrently, evaluated AT7519M in relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) using the recommended phase II dosing of 27mg/m2 twice weekly for 2 of every 3 weeks. Primary objective was objective response rate (ORR).

The results of these studies indicated AT7519M was safely administered to patients with relapsed/refractory CLL and MCL.

Seftel MD, Kuruvilla J, Kouroukis T, Banerji V, Fraser G, Crump M, Kumar R, Chalchal HI, Salim M, Laister RC, Crocker S, Gibson SB, Toguchi M, Lyons JF, Xu H, Powers J, Sederias J, Seymour L, Hay AE. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group (ONLINE). Leuk Lymphoma 1-8, 2016.

http://www.tandfonline.com/doi/full/10.1080/10428194.2016.1239259?scroll=top&needAccess=true